Reactions 1704, p78 - 2 Jun 2018 Thrombocytopenia: case report In a study of 25 patients, a patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with capecitabine [duration of treatment to reaction onset not stated]. The patient, who had rectal carcinoma, received neoadjuvant chemo-radiotherapy. The patient received oral capecitabine 825 mg/m in two daily doses along with radiotherapy 2Gy per day. The patient received a total dose of 44Gy and completed radiotherapy without any complications. However, while receiving capecitabine chemotherapy, the patient developed grade III thrombocytopenia. As a result, the patient’s capecitabine chemotherapy was discontinued prematurely [outcome not stated]. Author comment: "Concomitant chemotherapy was discontinued prematurely in one patient because of grade III thrombocytopenia." "[C]oncomitant chemotherapy was discontinued prematurely in one patient because of hematological toxicity." Richter I, et al. The prognostic effect of neoadjuvant chemoradiotherapy on the change of PD-L1 expression in patients with locally advanced rectal adenocarcinoma. Journal of B. U. ON: Official Journal of the Balkan Union of Oncology 22: 875-881, No. 4, Jul-Aug 2017. Available from: URL: https:// www.jbuon.com/pdfs/875-881.pdf - Czech Republic 803323269 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera